The digestive system cancers such as liver, gastric, esophagus, colon, and pancreas represent a group of cancers that manifest within both genetic and epigenetic changes which contribute to the tumourigenesis and progression of human cancers. Although precision medicine has been increasingly incorporated into clinical practice and is enabling cancer prevention and treatment, the genetic and epigenetic-related molecular markers with high sensitivity and specificity that are being used in clinical diagnosis, treatment, and prognosis are still unsatisfactory, especially the molecular mechanism involved in tumor occurrence, development and treatment needs to be further explored and verified.
This Research Topic focuses on the latest advances in genetic and epigenetic mechanisms concerning the occurrence, progression, and treatment of digestive system cancers and discoveries in precision medicine research. We hope this research topic will lead to a better understanding of genetic, epigenetic, and precision medicine research in the progression, diagnosis, and treatment of digestive system cancers and even other types of cancer.
We welcome submissions of original research and reviews of the following types, including but not limited to the themes below.
--Novel modifications of DNA, RNA, and proteins in tumorigenesis, progression, and therapy.
--Genetic and epigenetic regulation in carcinogenesis, progression, and therapy.
--Precision medicine research based on genetic polymorphism and pharmacogenomics.
--Development of novel genetic and epigenetic diagnostic, occurrence and prognosis biomarkers.
--Epigenetic mechanism underlying western medicine and traditional Chinese medicine therapies for patients with digestive system cancers.
--Frontier achievements in genetics and epigenetics related to other types of cancer may also be considered.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of a single public genomic or transcriptomic database which are not accompanied by validation cohorts are out of the scope of this section and will not be accepted as part of this Research Topic. However, bioinformatics analysis with high quality or new analytical methods is also in the scope of this section
The digestive system cancers such as liver, gastric, esophagus, colon, and pancreas represent a group of cancers that manifest within both genetic and epigenetic changes which contribute to the tumourigenesis and progression of human cancers. Although precision medicine has been increasingly incorporated into clinical practice and is enabling cancer prevention and treatment, the genetic and epigenetic-related molecular markers with high sensitivity and specificity that are being used in clinical diagnosis, treatment, and prognosis are still unsatisfactory, especially the molecular mechanism involved in tumor occurrence, development and treatment needs to be further explored and verified.
This Research Topic focuses on the latest advances in genetic and epigenetic mechanisms concerning the occurrence, progression, and treatment of digestive system cancers and discoveries in precision medicine research. We hope this research topic will lead to a better understanding of genetic, epigenetic, and precision medicine research in the progression, diagnosis, and treatment of digestive system cancers and even other types of cancer.
We welcome submissions of original research and reviews of the following types, including but not limited to the themes below.
--Novel modifications of DNA, RNA, and proteins in tumorigenesis, progression, and therapy.
--Genetic and epigenetic regulation in carcinogenesis, progression, and therapy.
--Precision medicine research based on genetic polymorphism and pharmacogenomics.
--Development of novel genetic and epigenetic diagnostic, occurrence and prognosis biomarkers.
--Epigenetic mechanism underlying western medicine and traditional Chinese medicine therapies for patients with digestive system cancers.
--Frontier achievements in genetics and epigenetics related to other types of cancer may also be considered.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of a single public genomic or transcriptomic database which are not accompanied by validation cohorts are out of the scope of this section and will not be accepted as part of this Research Topic. However, bioinformatics analysis with high quality or new analytical methods is also in the scope of this section
